Head-To-Head Analysis: Scinai Immunotherapeutics (NASDAQ:SCNI) vs. Cardio Diagnostics (NASDAQ:CDIO)

Cardio Diagnostics (NASDAQ:CDIO) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends.

Valuation and Earnings

This table compares Cardio Diagnostics and Scinai Immunotherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10,000.00	553.52	-$6.50 million	($2.92)	-0.64
Scinai Immunotherapeutics	$1.31 million	0.64	-$8.31 million	($95.34)	-0.01

Cardio Diagnostics has higher earnings, but lower revenue than Scinai Immunotherapeutics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Cardio Diagnostics and Scinai Immunotherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1	0	0	0	1.00
Scinai Immunotherapeutics	1	0	0	0	1.00

Institutional & Insider Ownership

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cardio Diagnostics and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Scinai Immunotherapeutics	N/A	N/A	N/A

Volatility and Risk

Cardio Diagnostics has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500.

Summary

Scinai Immunotherapeutics beats Cardio Diagnostics on 7 of the 11 factors compared between the two stocks.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.